(0.11%) 5 475.53 points
(0.11%) 39 156 points
(0.44%) 17 795 points
(-0.21%) $80.66
(-3.66%) $2.66
(-0.76%) $2 313.00
(0.18%) $28.92
(3.48%) $1 020.70
(0.26%) $0.936
(0.70%) $10.68
(0.45%) $0.792
(-0.28%) $87.25
Live Chart Being Loaded With Signals
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD)...
Stats | |
---|---|
今日成交量 | 1.79M |
平均成交量 | 1.22M |
市值 | 9.56B |
EPS | $-0.700 ( Q1 | 2023-05-09 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-56.47 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $2.40 (1.20%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-06-16 | Hendrix Martin | Sell | 2 071 | Common Stock |
2023-06-16 | Hendrix Martin | Sell | 40 000 | Stock Option (right to buy) |
2023-06-16 | Hendrix Martin | Sell | 20 500 | Stock Option (right to buy) |
2023-06-16 | Laur James | Sell | 2 071 | Common Stock |
2023-06-16 | Laur James | Sell | 40 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
-86.93 |
Last 100 transactions |
Buy: 394 552 | Sell: 5 154 734 |
音量 相关性
Prometheus Biosciences, 相关性 - 货币/商品
Prometheus Biosciences, 财务报表
Annual | 2023 |
营收: | $6.81M |
毛利润: | $6.81M (100.00 %) |
EPS: | $-3.49 |
FY | 2023 |
营收: | $6.81M |
毛利润: | $6.81M (100.00 %) |
EPS: | $-3.49 |
FY | 2022 |
营收: | $3.13M |
毛利润: | $3.13M (100.00 %) |
EPS: | $-2.87 |
FY | 2020 |
营收: | $1.23M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.376 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Prometheus Biosciences,
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。